Specialty Pharmaceutical Company dedicated to patients living with chronic conditions

BioDelivery Sciences to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

February 20, 2020

RALEIGH, N.C., Feb. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its fourth quarter and full year 2019 financial results after the close of the U.S. financial markets on Thursday, March 12, 2020. The company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:  Thursday, March 12, 2020
Time: 4:30 PM Eastern Time
Domestic: 877-407-0789
International: 201-689-8562
Conference ID: 13699178
Webcast: http://public.viavid.com/index.php?id=138131

About BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain, opioid dependence, and opioid-induced constipation.

© 2020 BioDelivery Sciences International, Inc.  All rights reserved.

Contact:
Tirth T. Patel
Director of Investor Relations
tpatel@bdsi.com
(919) 582-0294

1.jpg

Source: BioDelivery Sciences International

BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
Thank you. We will get back to you soon